CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma
Authors:
Open Access
- 11 January 2018
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 46 (3) , 1209-1220
Abstract
Neuroblastoma (NB) is the most common pediatric solid tumor derived from the sympathetic nervous system. MYCN is amplified in nearly half of patients with NB, and its association with rapid disease progression and poor outcome is controversial. Characterization of cancer stem cells (CSCs) in NBs has been rarely studied. This study was performed to determine whether MYCN and CD133+ CSCs are associated with chemotherapy resistance and the survival time of patients with NB. Fifty patients with an unequivocal pathological diagnosis of NB were recruited. MYCN expression levels were measured before therapy. CSCs were derived and their multipotency tested by directed differentiation. The patients’ responses to chemotherapy and average survival time were compared among the groups as follows: CD133+, CD133−, MYCN amplification ≥5 times (i.e. MYCN≥5), MYCNMYCN≥5, and CD133− plus MYCNMYCN≥5 patients had a significantly shorter average survival time than did CD133− plus MYCNMYCN amplification can be used together as a prognostic indicator of disease outcome.Keywords
This publication has 25 references indexed in Scilit:
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialThe Lancet Oncology, 2013
- International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology CommitteeBritish Journal of Cancer, 2009
- Loss of the Cholesterol-Binding Protein Prominin-1/CD133 Causes Disk Dysmorphogenesis and Photoreceptor DegenerationThe Journal of Neuroscience, 2009
- Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group DatabaseJournal of Clinical Oncology, 2009
- VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the Société Française des Cancers de l'Enfant (SFCE)Pediatric Blood & Cancer, 2009
- Stem cell concepts renew cancer researchBlood, 2008
- Cancer stem cells in solid tumours: accumulating evidence and unresolved questionsNature Reviews Cancer, 2008
- Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem CellsCancer Research, 2006
- Intestinal lymphangiectasia as a first manifestation of neuroblastomaPediatric Blood & Cancer, 2005
- Rat Prominin, Like Its Mouse and Human Orthologues, Is a Pentaspan Membrane GlycoproteinBiochemical and Biophysical Research Communications, 2001